We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


YM BioSciences Announces Positive Results from CYT997 Phase I Study

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "YM BioSciences Announces Positive Results from CYT997 Phase I Study"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:
YM BioSciences Inc. has announced the publication of Phase I results demonstrating that CYT997, a novel vascular disrupting agent (VDA), was well tolerated at doses that were associated with pharmacodynamic evidence of vascular disruption in tumors.

The article entitled "Phase I trial of CYT997, a novel cytotoxic and vascular-disrupting agent," was published in the premier cancer journal, the British Journal of Cancer. CYT997 is an orally bioavailable agent with dual mechanisms of vascular disruption and cytotoxicity and has the potential to be broadly active against a range of tumor types. CYT997 is currently in a Phase II clinical trial for glioblastoma multiforme, a brain cancer with poor prognosis, with data expected in Q2 2011.

"The ability of solid tumors to grow blood vessels is essential to their survival, growth and metastasis. Vascular disrupting agents such as CYT997, that damage or inhibit the formation of tumor blood vessels, have the potential for significant anti-cancer activity," said Dr. Nick Glover, COO of YM BioSciences.

"In addition to its broad applicability and the favorable safety results reported in the British Journal of Cancer, we were also very encouraged to observe promising signs of disease control in this study, particularly as CYT997 was given as monotherapy. Furthermore, CYT997 can be administered both orally and intravenously, which differentiates this molecule from most other VDAs in development which can only be administered intravenously."